Real World and Genomic Data Based Asthma Insight Through Network Analysis
NCT06623435 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1073
Last updated 2025-09-04
Summary
A retrospective and prospective observational study of asthma designed to determine real-world and molecular description of asthma according to treatment and type 2 biology
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
GeneDx
collaborator UNKNOWN -
National Jewish Health
collaborator OTHER -
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Linda Rogers, MD · Icahn School of Medicine at Mount Sinai
-
Ke Hao, PhD · Icahn School of Medicine at Mount Sinai
-
Eileen Wang, MD · National Jewish Health
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-11-07
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- United States
Study Locations
More Related Trials
-
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
NCT05270278 ·Status: COMPLETED
-
Functional Medicine in Asthma (FAst) Study
NCT02808689 ·Status: COMPLETED ·Phase: NA
-
Genetic Risk Factors for Severe Asthma
NCT00090740 ·Status: COMPLETED
-
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
NCT02502890 ·Status: COMPLETED
-
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
NCT01362621 ·Status: COMPLETED
-
Asthma Mobile Health Application 2.0
NCT03248869 ·Status: COMPLETED ·Phase: NA
-
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
GSNOR Phenotyping/GSNO Challenge in Severe Asthma
NCT03926741 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
NCT02999711 ·Status: COMPLETED ·Phase: PHASE1
-
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2
NCT01224951 ·Status: UNKNOWN ·Phase: NA
-
Cross-sectional Study for Identification and Description of Severe Asthma Patients
NCT02293265 ·Status: COMPLETED ·Phase: PHASE3
-
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
NCT06299306 ·Status: TERMINATED
-
The Role of Epigenetics in Inner City Asthma
NCT01382836 ·Status: COMPLETED
-
TNF Alpha in Refractory Asthma
NCT00276029 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma
NCT01577953 ·Status: COMPLETED ·Phase: PHASE1
-
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413 ·Status: RECRUITING
-
Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System
NCT06389058 ·Status: ACTIVE_NOT_RECRUITING
-
Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks
NCT05870215 ·Status: COMPLETED
-
Genetic Studies in Difficult to Treat Asthma: TENOR
NCT00091767 ·Status: COMPLETED
-
Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma
NCT01589198 ·Status: COMPLETED
-
Genetic Epidemiology of Asthma in Costa Rica
NCT00021840 ·Status: COMPLETED
-
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Study of the Mechanisms of Asthma
NCT00595153 ·Status: COMPLETED ·Phase: PHASE1
-
Develop and Implement Asthma Controlling Strategies (2)
NCT00005733 ·Status: COMPLETED
-
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
NCT05002621 ·Status: COMPLETED